Tirbanibulin ointment 1% in actinic keratosis: a profile of its use in the USA

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest A. McGuigan and Y. Y. Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here. 

  

Abstract 

Tirbanibulin ointment 1% (KLISYRI®) is an effective and well-tolerated novel topical treatment option for actinic keratosis (AK) in an area of up to 100 cm2 on the face or scalp of adults. It inhibits keratinocyte proliferation by blocking tubulin polymerization and Src kinase signaling pathways. A short course of once-daily self-applied tirbanibulin ointment 1% for five days results in significantly higher complete (100%) and partial (≥ 75%) clearance rates of AKs on the face or scalp compared with vehicle control. Tirbanibulin ointment 1% applied to an area up to 100 cm2 is generally well tolerated, with a low incidence of severe local skin reactions (LSRs) and systemic adverse events (AEs).

  

© Springer Nature Switzerland AG 2025